3401 N. Central Avenue Chicago, IL 60634

Boehringer Ingelheim

Boehringer Ingelheim


Study purpose:

The primary purpose of this Phase 2 trial is to assess the safety and efficacy of different doses of study medication BI-1358894 compared to placebo in patients with Major Depressive Disorder (MDD) with inadequate response to ongoing antidepressant therapy (ADT)

What is the medication?

BI 1358894. Participants will be asked to stay on a stable dose regimen of their current ADT during the treatment period while exposed to BI 1358894


Screening period: up to 30 days

Treatment period: 6 weeks

You May Qualify If:

You have been diagnosed with MDD, are in a major depressive episode, and have been treated for at least 4 weeks prior to screening with an approved antidepressant (ADT) and experiencing inadequate response.

Qualified candidates may earn up to ____ per visit. Transportation assistance to those who enroll.

Contact Us